The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs

PHASE3CompletedINTERVENTIONAL
Enrollment

5,178

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

February 29, 2012

Study Completion Date

March 31, 2012

Conditions
HIV-1
Interventions
DRUG

TMC125

200 mg b.i.d. till commercially available.

Trial Locations (259)

Unknown

Anniston

Birmingham

Phoenix

Tucson

Anaheim

Arcata

Bakersfield

Beverly Hills

Fontana

Fountain Valley

Garden Grove

Harbor City

Hayward

Loma Linda

Long Beach

Los Angeles

Newport Beach

Oakland

Palm Springs

Panorama City

Sacramento

San Diego

San Francisco

San Mateo

San Rafael

Santa Ana

Santa Clara

Santa Clarita

Santa Rosa

Stanford

Tarzana

Ukiah

Woodland Hills

Denver

Wheat Ridge

Glastonbury

New Haven

Norwalk

Norwich

Washington D.C.

Daytona Beach

Fort Lauderdale

Fort Laudersale

Hollywood

LaBelle

Leesburg

Miami

North Miami Beach

North Palm Beach

Orlando

Pensacola

Plantation

Port Saint Lucie

Safety Harbor

Sarasota

Tampa

Tarpon Springs

Vero Beach

West Palm Beach

Winter Park

Atlanta

Jesup

Macon

Riverdale

Savannah

Tucker

Honolulu

Aurora

Chicago

Maywood

Indianapolis

Des Moines

Iowa City

Henderson

Paducah

New Orleans

Ellsworth

Portland

Baltimore

Silver Spring

Boston

Springfield

Ann Arbor

Detroit

Grand Rapids

Grosse Pointe Woods

Minneapolis

Rochester

Saint Louis Park

Kansas City

St Louis

Lincoln

Las Vegas

Rochester

Englewood

Hackensack

Long Branch

Neptune City

Newark

Perth Amboy

Somers Point

Voorhees Township

Westfield

Santa Fe

Briarcliff

Brooklyn

Buffalo

East Meadow

Elmira

Flushing

Kingston

Manhasset

New York

Rochester

Staten Island

The Bronx

Chapel Hill

Gastonia

Huntersville

Winston-Salem

Akron

Cleveland

Columbus

Dayton

Portland

Allentown

Johnstown

Philadelphia

Pittsburgh

Providence

Columbia

Johnson City

Nashville

Austin

Dallas

El Paso

Fort Worth

Harlingen

Houston

Longview

San Antonio

Annandale

Charlottesville

Fairfax

Hampton

Norfolk

Richmond

Olympia

Seattle

Spokane

Yakima

Charleston

La Crosse

Madison

Milwaukee

Antwerp

Bruges

Brussels

Charleroi

Ghent

Leuven

Liège

Calgary

Edmonton

Vancouver

Winnipeg

Moncton

Hamilton

Kingston

London

Ottawa

Toronto

Whitby

Windsor

Montreal

Ste-Foy

Aarhus

Copenhagen

Hvidovre

Odense

Aachen

Berlin

Bochum

Bonn

Cologne

Düsseldorf

Erlangen

Essen

Frankfurt

Freiburg im Breisgau

Hamburg

Hanover

Mainz

Mannheim

Munich

München

Münster

Osnabrück

Stuttgart

Würzburg

Athens

Pátrai

Thessalonikis

Luxembourg

Bosques Del Nogalar San Nicola

Chihuahua City

Col Tacuba

Guadalajara

Mexico City

Monterrey Nuevo León

Puebla City

Tijuana

Alkmaar

Amsterdam

Amsterdam-Zuidoost

Arnhem

Groningen

Leiden

Maastricht

Nijmegen

Rotterdam

The Hague

Tilburg

Utrecht

San Juan

Moscow

Saint Petersburg

Volgograd

Kyungki

Pusan

Seoul

Alicante

Barcelona

Bilbao

Cadiz

Cuenca

Elche

Granada

Granollers

Logroño

Madrid

Málaga

Murcia

Oviedo

Sabadell

San Cristóbal de La Laguna

Santa Cruz de Tenerife

Santiago de Compostela (La Cor

Seville

Terrassa

Valencia

Vigo

Vitoria-Gasteiz

Gothenburg

Malmo

Stockholm

Kaohsiung City

Taipei

Ankara

All Listed Sponsors
lead

Tibotec Pharmaceuticals, Ireland

INDUSTRY

NCT00354627 - The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs | Biotech Hunter | Biotech Hunter